## A. For Equity Issues

Name of the issue:DIPNA PHARMACHEM LIMITED
Hame of the Issue. Dir Itali HAMMACHEM EMMILED

1 Type of issue (IPO/ FPO) Initial Public Offering (IPO) on SME Platform of BSE Limited
---

2 Issue size (Rs crore) Rs. 15.21 Crore

Since the issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018 there is no requirement of appointing a IPO Grading agency. 3 Grade of issue alongwith name of the rating agency

4 Subscription level (number of times). If the issue was undersubscribed, please clarify how the funds were arranged.

5 QIB holding (as a % of total outstanding capital) as disclosed to stock exchanges (See Clause 35 of the listing agreement)

(n) 11 - 11 - 11 - 11 - 11 - 11 - 11 - 11	,	T
(i) allotment in the issue	Nil	
(ii) at the end of the 1st Quarter		
immediately after the listing of the	Nil	
issue		
(iii) at the end of 1st FY	will b	e updated at the end of 1st F.Y.
(iv) at the end of 2nd FY	will b	e updated at the end of 2nd F.Y.
(v) at the end of 3rd FY	will b	e updated at the end of 3rd F.Y.
*Will be updated once the company makes necessary disc	losures on the website of BSE L	td.

6 Financials of the issuer (as per the annual financial results submitted to stock exchanges under Regulation 33 of the SEBI(LODR)

(Rs. in Lakhs)

Parameters	1st FY (2022-23)	2nd FY (2023-24)	3rd FY (2024-25)
Income from operations	9,992.72	will be	will be
Net Profit for the period	91.19	updated at	updated at
Paid-up equity share capital	1,197.00	the end of	the end of
Reserves excluding revaluation reserves	1,238.80	2nd F.Y.	3rd F.Y.

7 Trading status in the scrip of the issuer (whether frequently traded (as defined under Regulation 2 (j) of SEBI (SAST) Regulations, 2011) or infrequently traded/ delisted/

suspended by any stock exchange, etc.)

(i) at the end of 1st FY	Frequently Traded
(ii) at the end of 2nd FY	will be updated at the end of 2nd F.Y.
(iii) at the end of 3rd FY	will be updated at the end of 3rd F.Y.

8 Change, if any, in directors of issuer from the disclosures in the offer document (See Clause 34 of the SEBI(LODR)Regulations, 2015

(i) at the end of 1st FY	Yes, Chinu kalal- Independent Director w.e.f. 7th September, 2022 resigned w.e.f. 31st January, 2023, nandish jani Independent Director w.e.f. 7th September, 2022, jitendra parmar Additional Independent Director w.e.f. 1st May, 2023
(ii) at the end of 2nd FY	will be updated at the end of 2nd F.Y.
(iii) at the end of 3rd FY	will be updated at the end of 3rd F.Y.

## TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS

9 Status of implementation of project/ commencement of commercial production (as submitted to stock exchanges under Clause 41 (IV) (e) of the listing agreement)

			(Rs. In Lacs)
Objects of the issue (Rs in Lacs)	as disclosed in the	Actual	Reasons for
Objects of the issue (RS III Lacs)	offer document	implementation*	delay in
Working capital requirement	1110	1110	
General Corporate Purposes	365	365	NA.
Issue Related Expenses	45.76	45.76	I NA
TOTAL	1520.76	1520.76	

<sup>\*</sup> Source: BSE filing Reg 32(1) of SEBI(LODR) Reg, 2015

10 Status of utilization of issue proceeds (as submitted to stock exchanges under Clauses 41, 43 and 43A of the listing agreement)

	(Rs. In Lacs)
(i) as disclosed in the offer document	1520.76
(ii) Actual utilization	1520.76
(iii) Reasons for deviation, if any	NA

11 Comments of monitoring agency, if applicable (See Regulation 16 of SEBI (ICDR) Regulations, 2009 read with Clause 43A of the listing agreement)

NA

(To be submitted till the time the issue proceeds have been fully utilised)

12 Price- related data

Issue price (Rs):	38
•	

Price parameters	At close of listing day	At close of 30th	At close of 90th	As at the end of 1s	st FY after the I	isting of the	As at the	e end of 2nd	l FY after	As at the	e end of 3r	d FY after
, noo parameter	08.09.2022	calendar day from listing day	r day from calendar day from issue the listing of the issue								isting of the	
				Closing price	High	Low	Closing	High	Low	Closing	High	Low
					(during the	(during	price	(during	(during	price	(during	(during
					FY)	the FY)		the FY)	the FY)		the FY)	the FY)
Market Price	33.4	22.4	21	12.55	33.6	10.5						
Index (of the Designated Stock	59,688.22	58191.29	62,626.36	58,991.52	63,583.07	50,921.22						
Exchange):												
Sectoral Index (mention the index that has	23,091.22	23,643.22	23696.59	21883.5	25129.65	20847.55						
been considered and reasons for												1
considering the same)												

\*No sectoral Index available for the Pharmacutical Industry

2

## TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS

13 Basis for Issue Price and Comparison with Peer Group & Industry Average (Source of accounting ratios of peer group and industry average may be indicated; source of the accounting ratios may generally be the same, however in case of different sources, reasons for the same may be indicated)

Accounting ratio	Name of company	As disclosed in the offer document	At the end of 1st FY	At the end of 2nd FY	At the end of 3rd FY
	Issuer:	333.4	260.55		
	Peer Group:				
EPS	Earum Pharmaceuticals Limited	0.14	0.321		
	A-1 Acid Limited	2.73	3.140		
	Industry Avg:	1.435			
	Issuer:	0.11	0.048		
	Peer Group:	0.11	0.040		
P/E	Earum Pharmaceuticals				
	Limited	31.33	6.573		
	A-1 Acid Limited	107.51			
	Industry Avg:	69.42			
	Issuer:	67.12	2		
	Peer Group:				
	Earum				
RoNW	Pharmaceuticals				
	Limited	0.81	0.11		
	A-1 Acid Limited	6.79	0.075		
	Industry Avg:	3.8	0.09		
	Issuer:	496.74	20.35		
	Peer Group:				
	Earum				
NAV per share based on balance sheet	Pharmaceuticals				will be
	Limited	23.51	3.03		updated at
	A-1 Acid Limited	40.21	42.09	will be updated at	the end of
	Industry Avg:	31.86	22.56	the end of 2nd F.Y.	3rd F.Y.

<sup>14</sup> Any other material information

(i) Merchant Banker can give its comments on any of the above sections (ii) Merchant Banker may obtain information/ clarification from the issuer or stock exchange, wherever felt necessary (iii) In case any of the above reporting dates happens to be a holiday, the immediately following working day may be taken